AU2003254177A1 - Substituted benzanilides as modulators of the ccr5 receptor - Google Patents
Substituted benzanilides as modulators of the ccr5 receptorInfo
- Publication number
- AU2003254177A1 AU2003254177A1 AU2003254177A AU2003254177A AU2003254177A1 AU 2003254177 A1 AU2003254177 A1 AU 2003254177A1 AU 2003254177 A AU2003254177 A AU 2003254177A AU 2003254177 A AU2003254177 A AU 2003254177A AU 2003254177 A1 AU2003254177 A1 AU 2003254177A1
- Authority
- AU
- Australia
- Prior art keywords
- modulators
- ccr5 receptor
- substituted benzanilides
- benzanilides
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40008502P | 2002-07-31 | 2002-07-31 | |
| US60/400,085 | 2002-07-31 | ||
| PCT/US2003/023343 WO2004011427A2 (en) | 2002-07-31 | 2003-07-28 | Substituted benzanilides as modulators of the ccr5 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003254177A8 AU2003254177A8 (en) | 2004-02-16 |
| AU2003254177A1 true AU2003254177A1 (en) | 2004-02-16 |
Family
ID=31188660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003254177A Abandoned AU2003254177A1 (en) | 2002-07-31 | 2003-07-28 | Substituted benzanilides as modulators of the ccr5 receptor |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003254177A1 (en) |
| WO (1) | WO2004011427A2 (en) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7230022B2 (en) | 2004-02-19 | 2007-06-12 | Bristol-Myers Squibb Company | Substituted fused bicyclic amines as modulators of chemokine receptor activity |
| US7479496B2 (en) | 2004-02-19 | 2009-01-20 | Bristol-Myers Squibb Company | Substituted spiro azabicyclics as modulators of chemokine receptor activity |
| US7288563B2 (en) | 2004-02-19 | 2007-10-30 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
| US7381738B2 (en) | 2004-02-19 | 2008-06-03 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
| CN101005842A (en) | 2004-05-28 | 2007-07-25 | 弗特克斯药品有限公司 | Modulators of muscarinic receptors |
| US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| JP2008510728A (en) | 2004-08-19 | 2008-04-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | Muscarinic receptor modulators |
| KR20070057965A (en) | 2004-09-21 | 2007-06-07 | 신타 파마슈티칼스 코프. | Compounds for inflammation and immune-related uses |
| WO2006058303A2 (en) | 2004-11-29 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| DK1836169T5 (en) | 2004-12-28 | 2023-10-09 | Atnx Spv Llc | COMPOSITIONS AND METHODS FOR TREATING CELL PROLIFERATION DISORDERS |
| EP1846372B1 (en) | 2005-01-07 | 2014-04-16 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| JP2009527568A (en) | 2006-02-22 | 2009-07-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | Modulator of muscarinic receptor |
| CA2656564C (en) | 2006-06-29 | 2015-06-16 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| CN101500565A (en) | 2006-06-29 | 2009-08-05 | 弗特克斯药品有限公司 | Modulators of muscarinic receptors |
| WO2008002676A2 (en) * | 2006-06-29 | 2008-01-03 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| MX2009004314A (en) | 2006-11-13 | 2009-05-05 | Pfizer Prod Inc | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof. |
| US7935697B2 (en) | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
| US7939529B2 (en) | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
| TWI457336B (en) | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | Composition and methods for modulating a kinase cascade |
| WO2009009041A2 (en) | 2007-07-06 | 2009-01-15 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
| ES2645367T3 (en) | 2010-04-16 | 2017-12-05 | Athenex, Inc. | Compositions and methods for cancer prevention and treatment |
| MX359634B (en) | 2011-12-21 | 2018-10-03 | Novira Therapeutics Inc | Hepatitis b antiviral agents. |
| NZ704748A (en) | 2012-08-28 | 2018-06-29 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| CN105263907B (en) | 2012-08-30 | 2018-11-20 | 阿西纳斯公司 | N- (3- luorobenzyl) -2- (5- (4- morphlinophenyl) pyridine -2- base) acetamide as protein tyrosine kinase regulator |
| PL2961732T3 (en) | 2013-02-28 | 2017-09-29 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| JO3603B1 (en) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| AP2015008968A0 (en) | 2013-07-25 | 2015-12-31 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b |
| UA117261C2 (en) | 2013-10-23 | 2018-07-10 | ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| EP3102225B1 (en) | 2014-02-05 | 2020-03-25 | Novira Therapeutics Inc. | Combination therapy for treatment of hbv infections |
| KR20160110419A (en) | 2014-02-06 | 2016-09-21 | 얀센 사이언시즈 아일랜드 유씨 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| WO2016149581A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| AU2016330964B2 (en) | 2015-09-29 | 2021-04-01 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
| WO2017181141A2 (en) | 2016-04-15 | 2017-10-19 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
| KR20200131816A (en) | 2018-03-14 | 2020-11-24 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Capsid assembly modulator dosing regimen |
| CA3127152A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
| KR20220005549A (en) | 2019-05-06 | 2022-01-13 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Amide derivatives useful for the treatment of HBV infection or HBV-induced disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0001910A2 (en) * | 1997-04-18 | 2000-10-28 | Pfizer Inc. | Process and intermediates for the preparation of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (1,2,3,4-tetrahydro-isoquinolin-6-yl)-amide |
| WO2000006085A2 (en) * | 1998-07-28 | 2000-02-10 | Smithkline Beecham Corporation | Compounds and methods |
-
2003
- 2003-07-28 AU AU2003254177A patent/AU2003254177A1/en not_active Abandoned
- 2003-07-28 WO PCT/US2003/023343 patent/WO2004011427A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003254177A8 (en) | 2004-02-16 |
| WO2004011427A2 (en) | 2004-02-05 |
| WO2004011427A3 (en) | 2005-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003254177A1 (en) | Substituted benzanilides as modulators of the ccr5 receptor | |
| AU2003256923A1 (en) | Substituted benzanilides as modulators of the ccr5 receptor | |
| AU2003253535A1 (en) | N-4-piperidinyl compounds as ccr5 modulators | |
| AU2003281355A1 (en) | Modulators of the glucocorticoid receptor | |
| AU2003245773A1 (en) | Vanilloid receptor modulators | |
| AU2002353403A1 (en) | Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators | |
| AU2003231509A1 (en) | Compound exhibiting pgd 2 receptor antagonism | |
| AU2003259482A1 (en) | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators | |
| AU2003233465A1 (en) | Structural member | |
| AU2003290734A1 (en) | Novel compounds as pharmaceutical agents | |
| HK1076102A1 (en) | Tropane derivatives as ccr5 modulators | |
| AU2003256922A1 (en) | Substituted heterocyclic compounds as modulators of the ccr5 receptor | |
| AU2003300952A1 (en) | Indane compounds as ccr5 antagonists | |
| AU2003211453A1 (en) | External compositions for the skin | |
| AU2003218374A1 (en) | Substituted tetrahydroisoquinolines as c5a receptor modulators | |
| AU2003295355A1 (en) | Anchor | |
| AU2003301299A1 (en) | Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators | |
| AU2003217110A1 (en) | Novel formulation | |
| AU2003260983A1 (en) | Processes for the preparation of s-(-)-amlodipine | |
| AU2002367890A1 (en) | Process for the preparation of 4-methyl-thiazole-5-carbaldehyde intermediate | |
| AU2003232108A1 (en) | 1,1- and 1,2-bisphosphonates as apoliprotein e modulators | |
| AU2003278420A1 (en) | Process for the preparation of ganciclovir | |
| AU2003264443A1 (en) | Preparation for external use | |
| AU2003226396A1 (en) | Imidazolidine compounds as chemokine receptor modulators | |
| AU2003300867A1 (en) | Uses of the snorf207 receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |